Compare Vital Farms Inc (VITL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vital Farms Inc vs Viatris Inc — how do they compare? Vital Farms Inc trades at $11.45 (market cap $496.50M), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 37.6× Vital Farms Inc's market cap, and Viatris Inc pays a 2.95% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| VITL | VTRS | |
|---|---|---|
Market Cap | $496.50M | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $52.41 | $17.86 |
52-Week Low | $8.28 | $9.49 |
Enterprise Value | $583.51M | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vital Farms (VITL) trades at $11.52, up 2.31% today, amid bearish technical signals and challenging fundamentals. The stock shows oversold conditions with RSI at 29.21, while recent Q2 2026 results revealed a $0.47 per share loss despite beating revenue estimates. The company secured $125 million in financing to navigate industry oversupply pressures and elevated costs affecting profitability.
While analyst consensus remains positive with a $13.00 price target and no sell ratings, near-term headwinds from margin compression and net cash outflows pose significant risks. The stock's valuation appears reasonable with P/E of 11.77 and P/S of 0.67, but investors should monitor execution on cost management and revenue stabilization for sustainable recovery.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
